This chapter contains sections titled:

• Introduction

• Generic properties and characteristics of cyclic nucleotide phosphodiesterases

• Standardized nomenclature

• Theophylline, hybrid and nonselective PDE inhibitors

• Clinical pharmacology

• Adverse events of theophylline and PDE inhibitors

• Concluding remarks

• References